The estimated Net Worth of Charles G Iii Phillips is at least 599 千$ dollars as of 2 December 2019. Charles Phillips owns over 6,145 units of NovoCure Ltd stock worth over 57,876$ and over the last 9 years Charles sold NVCR stock worth over 541,436$.
Charles has made over 5 trades of the NovoCure Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently Charles sold 6,145 units of NVCR stock worth 541,436$ on 2 December 2019.
The largest trade Charles's ever made was exercising 95,100 units of NovoCure Ltd stock on 29 May 2019 worth over 871,116$. On average, Charles trades about 17,939 units every 92 days since 2015. As of 2 December 2019 Charles still owns at least 3,359 units of NovoCure Ltd stock.
You can see the complete history of Charles Phillips stock trades at the bottom of the page.
Charles's mailing address filed with the SEC is C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN, PA, 19355.
Over the last 9 years, insiders at NovoCure Ltd have traded over 237,132,855$ worth of NovoCure Ltd stock and bought 164,174 units worth 2,198,429$ . The most active insiders traders include Asaf Danziger、William Fwfd Ventures Fund ...、Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of 853,350$. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth 13,856$.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: